167 related articles for article (PubMed ID: 19508463)
1. Long-term exendin-4 treatment delays natural deterioration of glycaemic control in diabetic Goto-Kakizaki rats.
Simonsen L; Pilgaard S; Orskov C; Hartmann B; Holst JJ; Deacon CF
Diabetes Obes Metab; 2009 Sep; 11(9):884-90. PubMed ID: 19508463
[TBL] [Abstract][Full Text] [Related]
2. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4.
Tourrel C; Bailbe D; Lacorne M; Meile MJ; Kergoat M; Portha B
Diabetes; 2002 May; 51(5):1443-52. PubMed ID: 11978641
[TBL] [Abstract][Full Text] [Related]
3. Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice.
Park CW; Kim HW; Ko SH; Lim JH; Ryu GR; Chung HW; Han SW; Shin SJ; Bang BK; Breyer MD; Chang YS
J Am Soc Nephrol; 2007 Apr; 18(4):1227-38. PubMed ID: 17360951
[TBL] [Abstract][Full Text] [Related]
4. No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks.
Tatarkiewicz K; Belanger P; Gu G; Parkes D; Roy D
Diabetes Obes Metab; 2013 May; 15(5):417-26. PubMed ID: 23163898
[TBL] [Abstract][Full Text] [Related]
5.
Zambrana S; Lundqvist LCE; Mamani O; Catrina SB; Gonzales E; Östenson CG
Nutrients; 2018 Jul; 10(7):. PubMed ID: 30037028
[No Abstract] [Full Text] [Related]
6. The impact of improved glycaemic control with GLP-1 receptor agonist therapy on diabetic retinopathy.
Varadhan L; Humphreys T; Walker AB; Varughese GI
Diabetes Res Clin Pract; 2014 Mar; 103(3):e37-9. PubMed ID: 24456992
[TBL] [Abstract][Full Text] [Related]
7. A direct comparison of long- and short-acting GLP-1 receptor agonists (taspoglutide once weekly and exenatide twice daily) on postprandial metabolism after 24 weeks of treatment.
Gastaldelli A; Balas B; Ratner R; Rosenstock J; Charbonnel B; Bolli GB; Boldrin M; Balena R
Diabetes Obes Metab; 2014 Feb; 16(2):170-8. PubMed ID: 23911196
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotective effect of the glucagon-like peptide-1 receptor agonist, synthetic exendin-4, in streptozotocin-induced diabetic rats.
Liu WJ; Jin HY; Lee KA; Xie SH; Baek HS; Park TS
Br J Pharmacol; 2011 Nov; 164(5):1410-20. PubMed ID: 21323903
[TBL] [Abstract][Full Text] [Related]
9. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta).
Young AA; Gedulin BR; Bhavsar S; Bodkin N; Jodka C; Hansen B; Denaro M
Diabetes; 1999 May; 48(5):1026-34. PubMed ID: 10331407
[TBL] [Abstract][Full Text] [Related]
10. Roux-en-Y gastric bypass-induced improvement of glucose tolerance and insulin resistance in type 2 diabetic rats are mediated by glucagon-like peptide-1.
Liu Y; Zhou Y; Wang Y; Geng D; Liu J
Obes Surg; 2011 Sep; 21(9):1424-31. PubMed ID: 21479766
[TBL] [Abstract][Full Text] [Related]
11. Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations.
Greig NH; Holloway HW; De Ore KA; Jani D; Wang Y; Zhou J; Garant MJ; Egan JM
Diabetologia; 1999 Jan; 42(1):45-50. PubMed ID: 10027577
[TBL] [Abstract][Full Text] [Related]
12. The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide.
Guo XH
Curr Med Res Opin; 2016; 32(1):61-76. PubMed ID: 26439329
[TBL] [Abstract][Full Text] [Related]
13. Exendin-4 suppresses SRC activation and reactive oxygen species production in diabetic Goto-Kakizaki rat islets in an Epac-dependent manner.
Mukai E; Fujimoto S; Sato H; Oneyama C; Kominato R; Sato Y; Sasaki M; Nishi Y; Okada M; Inagaki N
Diabetes; 2011 Jan; 60(1):218-26. PubMed ID: 20978090
[TBL] [Abstract][Full Text] [Related]
14. Addition of or switch to insulin therapy in people treated with glucagon-like peptide-1 receptor agonists: A real-world study in 66 583 patients.
Montvida O; Klein K; Kumar S; Khunti K; Paul SK
Diabetes Obes Metab; 2017 Jan; 19(1):108-117. PubMed ID: 27629433
[TBL] [Abstract][Full Text] [Related]
15. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
[TBL] [Abstract][Full Text] [Related]
16. Effect of linagliptin, alone and in combination with voglibose or exendin-4, on glucose control in male ZDF rats.
Jones RB; Vickers SP; Cheetham SC; Headland KR; Mark M; Klein T
Eur J Pharmacol; 2014 Apr; 729():59-66. PubMed ID: 24530555
[TBL] [Abstract][Full Text] [Related]
17. Protection of exendin-4 analogue in early experimental diabetic retinopathy.
Zhang Y; Wang Q; Zhang J; Lei X; Xu GT; Ye W
Graefes Arch Clin Exp Ophthalmol; 2009 May; 247(5):699-706. PubMed ID: 19084986
[TBL] [Abstract][Full Text] [Related]
18. Exendin-4 ameliorates diabetic symptoms through activation of glucokinase.
Dhanesha N; Joharapurkar A; Shah G; Dhote V; Kshirsagar S; Bahekar R; Jain M
J Diabetes; 2012 Dec; 4(4):369-77. PubMed ID: 22356440
[TBL] [Abstract][Full Text] [Related]
19. Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes.
Egan JM; Meneilly GS; Elahi D
Am J Physiol Endocrinol Metab; 2003 Jun; 284(6):E1072-9. PubMed ID: 12475750
[TBL] [Abstract][Full Text] [Related]
20. Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus.
Briones M; Bajaj M
Expert Opin Pharmacother; 2006 Jun; 7(8):1055-64. PubMed ID: 16722815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
